Hepatic venocclusive disease (V0D) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinus is the initial event in the pathogenesis of VOD. What are less clear are the mechanisms of injury and whether this knowledge can be exploited. This manuscript will briefly review some recent data and discuss how that information has influenced clinical practice. Bone Marrow Transplantation (2001) 27, 1113-1120.
VOD is characterized by a syndrome of jaundice, fluid retention and painful hepatomegaly and occurs in up to half of patients who receive ablative preparative therapy. 1 As many as half of patients with VOD die, usually of multiorgan failure. Signs of VOD usually present around the day of transplant, 2 although well described 'late onset VOD' has been reported. 3, 4 Fluid retention and hepatomegaly are usually the first manifestations and typically present on or around the day of transplant. Jaundice develops later, around day 6. 2 The rate of rise in bilirubin and weight is also faster for patients whose illness is likely to be severe vs those who are likely to have self-limited disease. Furthermore, fewer than 20% of patients with mild VOD and 48% with severe VOD develop ascites. 2 These observations led to the development of a model p ϭ 1/(1 ϩ e Ϫz )
which would predict which patients with VOD were likely to die. 5 In this model, z ϭ ␤ 0 ϩ ␤ 1 (in total serum bilirubin) ϩ ␤ 2 (percent weight gain). The intercepts ␤ 0 , ␤ 1 and ␤ 2 change as day relative to transplant increases. 5 For or Ϫ0. 39 . The probability of developing severe VOD would therefore be 1/[1 ϩ e Ϫ(Ϫ0.39) ] or 0.40. This model has been shown to be highly specific but only moderately sensitive. Therefore, it is suitable for use to screen patients for therapeutic trials of investigational or potentially toxic agents. Richardson and colleagues 6 used the model to determine eligibility for treatment with defibrotide. Patients whose probability of developing fatal VOD was 40% or greater were eligible for that study.
Pathologic changes of VOD are centered in zone 3 of the liver acinus. Hepatic venular occlusion is the pathognomonic change described in the literature, although patients without this finding can develop the clinical syndrome. Other pathologic changes include eccentric venular luminal narrowing, phlebosclerosis, sinusoidal fibrosis, and necrosis of hepatocytes. 7 The severity of the clinical illness is strongly related to the number of pathologic changes in zone 3. Elevated hepatic venous pressure gradients also correlate with histologic features of VOD. 7 Increased platelet transfusion requirement is usually associated with VOD. Gordon et al 8 retrospectively reviewed platelet requirements in 199 patients who underwent transplant at the University of Nebraska. They found that patients with dysfunction of a single organ (VOD, pulmonary or CNS) received more platelet transfusions per week compared to patients without organ dysfunction. Furthermore, an increased number of platelet transfusions during any 1 week was predictive for development of organ toxicity, including VOD, in the subsequent week. Thrombocytopenia in VOD patients is not the result of a deficiency in thrombopoietin. 
Pathogenesis, prevention and treatment
Research in VOD pathogenesis has concentrated in several areas: glutathione depletion, inflammatory mediators, coagulation, and fibrogenesis. These areas of investigation frequently overlap. Not surprisingly, prevention (Table 1 ) Table 1 Approaches to prevention of VOD
Strategy Mechanism Comments
Heparin Prevents deposition of clotting material Only one randomized trial performed. Patients who received heparin had in terminal hepatic venules less VOD than those who did not receive heparin. 34 However, severe VOD was not different in the two groups. In addition, few patients were at high risk prior to transplant. In a single arm study of high risk patients, heparin was ineffective. 32 A randomized trial with low molecular weight heparin showed that the duration of signs of VOD (hyperbilirubinemia, hepatomegaly) was less in LMWH-treated patients. 36 Outcome between the two groups was not reported.
Ursodiol
?downregulates inflammatory mediators Two randomized trials have reported a lower incidence of VOD in ursodiol-treated patients. Survival was not different between the groups. 72, 73 N-acetylglucosamine precursor of glutathione Very few patients treated.
l-glutamine precursor of glutathione Very few patients treated.
and treatment (Table 2 ) studies have been based on these observations.
Glutathione
Zone 3 of the liver acinus contains the greatest concentration of cytochrome P450 and glutathione-S-transferase enzymes. 10, 11 P450 enzymes metabolize many chemotherapeutic agents while the glutathione-S-transferase enzymes catalyze the reaction of glutathione with electrophilic compounds. There is strong evidence that depletion of glutathione results in hepatocyte necrosis. 12 DeLeve 13 studied the effect of cyclophosphamide on sinusoidal endothelial cells (SEC) and hepatocytes in culture. She reported that direct exposure of SEC to cyclophosphamide did not result in toxicity while exposure to the cyclophosphamide metabolites acrolein or 4-hydroxycyclophosphamide resulted in a dramatic dose-dependent toxicity. When SEC and hepatocytes were cultured together in the presence of cyclophosphamide, SEC experienced significantly more toxicity than did hepatocytes. DeLeve postulated that toxicity to SEC was due to acrolein generated by the metabolic activation of cyclophosphamide by hepatocytes. This effect could be reversed by sustaining levels of hepatocyte glutathione with Table 2 Approaches to treatment of VOD serine and methionine. However, when propargylglycine, an inhibitor of glutathione synthesis was present, this protective effect was abolished. These studies suggest that increased exposure to the toxic metabolites of cyclophosphamide contribute to development of VOD and that supporting hepatocyte glutathione levels might prevent development of or reverse VOD. Recently, DeLeve and colleagues demonstrated that infusion of reduced glutathione could protect rats from VOD caused by monocrotaline, a pyrrolizidine alkaloid.
14 Three patients with VOD have been treated with N-acetylcysteine, a thiol antioxidant which is a precursor of intracellular reduced glutathione synthesis. 15 The diagnosis was made on days 10, 14, and 18 post transplant. All had at least a 10% weight gain and moderate hyperbilirubinemia. One had significant ascites, pleural effusions, and encephalopathy. Tissue plasminogen activator was given to all three patients for one to four doses. NAC was also given for 12-31 days. All patients recovered normal hepatic function and were alive 4, 8, and 9 months after transplant. Since all patients had a low probability of fatal VOD based on the model discussed above, 5 the relative contributions of tPA and NAC to the resolution of VOD cannot be fully ascertained.
Like NAC, glutamine is utilized by hepatocytes to replenish intracellular glutathione. 16 Two patients with VOD were treated using l-glutamine (in dipeptide form) plus vitamin E. 17 Although VOD resolved in both patients, the role of l-glutamine is difficult to determine. One of the patients had late-onset VOD, which is not considered in the above model. 5 The second patient had VOD earlier in the post-transplant course with a more fulminant presentation and may, indeed, have benefited from therapy.
The same group also studied l-glutamine as prophylaxis of liver toxicity after stem cell transplantation. 18 Eighteen patients were randomized to receive l-glutamine while 16 received non-essential amino acids. VOD did not occur in any patients. Thrombin-antithrombin (TAT), plasmin-␣2-antiplasmin (PAP), prothrombin fragment F1ϩ2, protein C and albumin were measured in all patients. The authors reported that mean protein C and albumin levels were significantly higher in the glutamine group on day 4 post transplant and suggest that glutamine may work by preserving protein C levels. However, since none of the patients not receiving glutamine developed VOD, despite lower protein C levels, the benefit of glutamine in VOD prophylaxis remains questionable.
Coagulation parameters
In 1987, Shulman et al 19 described the deposition of fibrinogen and factor VIII in vessel walls at the interface of hepatic sinusoids and terminal hepatic venules. This observation provided the rationale for studying the role of the clotting system in the pathogenesis of VOD. A number of investigators have found evidence consistent with hypercoagulable state at the start of the preparative regimen or in the early post-transplant period. These include deficiencies of protein C, antithrombin III, protein S and elevated levels of D-dimer and prothrombin fragment F1ϩ2. [20] [21] [22] [23] [24] [25] [26] [27] Why this is so is unclear. Deficiencies in protein C and antithrombin III (ATIII) in patients with VOD (or organ toxicity, in general) have been reported by numerous investigators. [20] [21] [22] [23] [24] Faioni et al 20 reported that baseline levels of protein C were lower in patients who developed VOD and continued to decrease post transplant. Tanikawa et al 21 and Gordon et al 22 reported that protein C levels decreased post transplant in patients who developed VOD. The University of Nebraska group also reported that ATIII levels fell after high-dose chemotherapy. 22 They also showed that patients who developed organ dysfunction had lower levels of ATIII than those without organ dysfunction. Low levels of protein C and ATIII post transplant both correlated with death. 23 There are several reports which suggested that VOD was more common in females. 28, 29 One possible explanation for this is the use of progestins to minimize menstrual bleeding during myelosuppression. Progestins have been associated with an increased risk of thromboembolic events, in part due to acquired protein C resistance. 30 Hägglund and colleagues 31 recently evaluated whether norethisterone administration might be associated with VOD. Fifty-five women transplanted between January 1990 and June 1995 received norethistherone and 38 did not. The incidence of VOD was 27% in women who received norethisterone and 3% in Bone Marrow Transplantation those who did not. A multivariate analysis, which also included male patients, showed norethisterone to be an independent predictor of VOD.
The studies above led to trials of various agents with anticoagulant activity in patients with VOD or to prevent VOD. The earliest studies, with perhaps the most disagreed upon results, used heparin. My colleagues and I administered heparin by continuous infusion to 28 patients at high risk for developing VOD. 32 Heparin was dosed to result in varying degrees of prolongation of the activated partial thromboplastin time. VOD occurred in 70% of patients, four of whom developed severe VOD. The incidence and severity of VOD was not influenced by the degree or duration of anticoagulation. Two patients at the highest dose level of heparin developed significant, but non-fatal hemorrhagic complications. Lack of benefit from heparin was also reported by Marsa-Vila et al. 33 On the other hand, there have been several studies supporting the use of heparin to prevent VOD. Attal and colleagues 34 conducted the only prospective randomized trial of heparin for VOD prophylaxis. They reported a 13.7% incidence of VOD in the non-treated group compared to 2.5% in the heparin-treated group (13.7% vs 2.5%). Severe VOD was not different between the two groups. Rosenthal et al 35 conducted a retrospective analysis of heparin prophylaxis in children. They found that heparin given from the start of preparative therapy until day ϩ30 (or discharge) resulted in significantly less VOD than historical controls (10% vs 28%). Moderate to severe VOD occurred in 4% of study patients and 9% of control patients.
More recently, Or et al 36 conducted a prospective randomized trial of low molecular weight (LMW) heparin vs placebo to prevent VOD. They reported a reduction in the duration of hyperbilirubinemia and the incidence of hepatomegaly in the LMW heparin-treated patients. They also reported that hemorrhagic complications were fewer, time to platelet recovery was shorter, and platelet transfusion requirements were less in the LMW heparin-treated patients. The degree of hyperbilirubinemia, fluid retention and outcome was not reported.
The efficacy of heparin remains in dispute. While all agree that low doses of heparin or LMW heparin can be safely administered in the transplant setting, most patients reported in the literature have a low likelihood of developing VOD based on pretransplant risk factors. The only study where most patients were at high risk showed no benefit. 32 I do not believe heparin is efficacious for prevention of VOD.
Several agents with antithrombotic activity have been studied. These include recombinant human tissue plasminogen activator, antithrombin III, and defibrotide. While recombinant tissue plasminogen activator (rh-tPA) has been used in many patients, only two series have included substantial numbers of patients. 37, 38 We reported that 29% of patients responded and that 24% developed life-threatening hemorrhage. In Scriber's series, 38 most patients began treatment when they were suspected to be developing VOD rather than after established criteria were met. Of 24 patients who were treated without having met criteria for VOD, 67% responded. The remaining 13 patients, who began treatment with established VOD, had a response rate of 23%. They, too, reported a very high incidence (35%) of clinically significant hemorrhage. We have ceased using rh-tPA because the risk of severe hemorrhage is about the same as the response rate. Treating patients with existing multiorgan dysfunction has been shown to be ineffective.
Antithrombin III has been administered to a small number of patients with VOD. 39, 40 Compared to historical controls not treated with ATIII, death due to VOD or multiorgan failure was significantly decreased. Platelet consumption, painful hepatomegaly and fluid retention resolved in the majority of patients.
Defibrotide (DF) is a single-stranded polydeoxyribonucleotide with anti-ischemic, antithrombotic and thrombolytic activity, but no significant anticoagulant effects. Richardson and coworkers 6, 41 have studied DF in 75 patients with severe VOD. Eighty-four percent of patients had ascites and 92% had evidence of multiorgan dysfunction. Of 67 patients treated for 4 or more days, the complete response rate was 35%. There was no significant toxicity. Patients younger than 18 years of age and those with dysfunction in no more than one additional organ system did better. Since responses were greater in patients prepared with cyclophosphamide-based regimens, the authors postulated that DF worked by repairing the endothelial damage known to occur as a result of high-dose cyclophosphamide.
Busulfan pharmacokinetics
The importance of busulfan in VOD pathogenesis has been the subject of intense investigation. Several investigators have reported that a higher busulfan area-under-the-curve of concentration vs time (AUC) or steady-state concentration is associated with an increased risk of developing VOD [42] [43] [44] [45] and that adjusting the dosage based on first dose pharmacokinetics can result in a decrease in VOD. 45, 46 Virtually all patients prepared for transplant using busulfan receive a combination of busulfan and cyclophosphamide. Slattery et al 47 found that the average plasma steadystate concentrations of busulfan correlated with exposure to cyclophosphamide. In their study comparing the pharmacokinetics in seven patients who received busulfan plus cyclophosphamide (BU/CY) with seven patients who received cyclophosphamide plus TBI (CY/TBI), they found that all measures of exposure to hydroxycyclophosphamide were greater in BU/CY patients than in CY/TBI. 47 This is consistent with the results of DeLeve (see Glutathione, above). Busulfan depletes glutathione, enhancing hydroxycyclophosphamide exposure and increasing toxicity.
Part of the difficulty in using busulfan is that the absorption from the gastrointestinal tract is unpredictable and the plasma levels, therefore, variable. Andersson et al 48 performed a phase I trial of a single dose of intravenous busulfan in patients being prepared for transplant with oral busulfan plus cyclophosphamide (15 additional doses). When compared with the bioavailability of the single dose of i.v. busulfan, the bioavailability of oral busulfan ranged from 10% to 100% (average 69%). The time to maximum plasma concentration and the clearance of the i.v. preparation was similar to that of oral busulfan. The optimal dose of i.v. busulfan was determined to be 0.8 mg/kg. Vaughan and colleagues 49 reported on the use of i.v. busulfan in two phase II studies. Of 103 patients transplanted, six developed VOD, which was fatal in two. The first dose mean busulfan AUC was 1156 mol/min for all patients and 1302 mol/min for the six VOD patients. The AUC observed in this trial are sufficient to ensure engraftment (known to be poor when drug exposure is low) 45 and to minimize the risk of VOD.
Inflammatory mediators
Alterations in plasma levels of several inflammatory mediators have been reported in patients with VOD. Holler et al 50 first reported in 1990 that patients with major complications of transplantation, ie acute graft-versus-host disease, idiopathic pneumonia, endothelial leak syndrome and VOD, had significant elevations in TNF-␣ levels after transplant which often preceded the clinical complication. Holler's initial observation was the impetus for studying pentoxifylline in regimen-related toxicities, which was ultimately found to be ineffective. 51 Other data for cytokine activation in VOD include increased expression of genes for interleukin-1␤ and TNF-␣ in peripheral blood mononuclear cells of patients who developed VOD, 52 as well as increased levels of circulating IL-2 receptor. 53 Khoury et al 54 studied whether high doses of corticosteroids given at the earliest evidence of VOD or liver dysfunction of unknown etiology alters the course of hepatic regimenrelated toxicity. Twenty-eight consecutive patients who met Seattle criteria for VOD or liver dysfunction of unknown etiology were treated with 500 mg/m 2 of methylprednisolone every 6 h for six doses. Seventeen patients (61%) responded as defined by a decrease in total bilirubin within 10 days of treatment. The only distinguishing factor between responders and nonresponders was that nonresponders had a lower pretransplant DLCO.
Generalized endothelial injury
Endothelial injury is clearly an early event in the pathogenesis of VOD. Circulating levels of the endothelial marker thrombomodulin [55] [56] [57] increase after high-dose cytoreductive therapy. Plasminogen activator inhibitor-1 (PAI-1), another endothelium-derived molecule, also increases after highdose cytoreductive therapy in patients with VOD. 58 Salat and colleagues 59 have shown that elevations in PAI-1 are specific for VOD and were not significantly elevated from other causes of liver injury. Successful treatment of VOD with DF lowers PAI-1 levels. 57 There is also evidence that the vascular endothelium may be injured and activated before the start of conditioning therapy, presumably due to previous chemotherapy. Richard and colleagues 60 measured the endothelial cell markers von Willebrand factor (vWF), soluble thrombomodulin, soluble intercellular adhesion molecule-1 (ICAM-1), and their inducers TNF-␣ and elastase in the plasma of patients prior to and 1 and 3 weeks after bone marrow transplant. They observed increases in ICAM-1 and vWF after transplant but no increases in thrombomodulin or TNF-␣. However, levels of thrombomodulin and vWF were increased at baseline, suggesting that endothelial injury already existed and that changes occurring after transplant were more consistent with endothelial activation rather than further damage. The Seattle group reported that the risk of dying within 6 months of stem cell transplantation was correlated with reduced diffusing capacity of carbon monoxide corrected for hemoglobin (DLCO) and increased alveolar-arterial oxygen gradient. 61 In a subsequent report, they showed that DLCO less than 70% of predicted was independently associated with an increased risk of severe VOD (odds ratio 2.4). 62 They, too, hypothesized that the decreased DLCO reflected systemic endothelial damage from prior therapy.
Fibrogenesis/fibrolysis
Fibrosis of centrilobular sinusoids is one of the classic histologic features of VOD and is the result of a balance between fibrogenesis and the dissolution of fibrosis (fibrolysis). How this comes about in VOD and why, has been the subject of studies by several groups of investigators.
Hepatic stellate cells are the most important mediators of hepatic fibrosis. 63 Activation of stellate cells results in induction of extracellular matrix genes, expression of smooth muscle-specific ␣ actin, and increases in types III and IV collagen. 64 Sato and colleagues 65 reported that significantly more stellate cells in zone 3 were activated in patients who developed VOD compared to those who did not. This results in production of the N-terminal propeptide of type III procollagen (PIIINP), which has been reported to be elevated in patients with VOD by several groups, 21, [66] [67] [68] as early as day 0. 68 Tanikawa et al 21 reported that PIIINP levels were elevated prior to the start of conditioning therapy, again suggesting that hepatic injury and repair processes had occurred or were ongoing at the time high-dose cytoreductive therapy began. In this study, however, pretransplant ALT and AST were not different between patients who did or did not develop VOD. It would be interesting to know whether patients whose transaminases are elevated prior to transplant also have elevated PIIINP levels.
Other molecules which promote fibrosis have also been studied in VOD patients. These include tenascin, a marker of fibrogenesis, and tissue inhibitor of metalloproteinase type 1 (TIMP-1), an inhibitor of fibrolysis, which are also elevated within 1 week of onset of VOD. 69 Thus, hepatic injury both increases fibrogenesis and inhibits fibrolysis. Unfortunately, how to exploit this information with regard to prevention and treatment is unclear.
A unifying hypothesis?
There are some data which suggest that particular TNF gene polymorphisms may be associated with organ injury. Cavet et al 70 reported that patients homozygous for TNFd microsatellite allele 3 (TNFd3) had a much greater likelihood of dying by day 30 than patients not homozygous for TNFd3 (24% vs 7%). Haire et al 71 followed 42 consecutive patients for development of VOD, pulmonary dysfunction and CNS dysfunction. The TNFd genotype of these patients was determined by polymerase chain reaction. Organ toxicity occurred in 57% of patients with at least one TNFd3 allele and 17% of patients with no TNFd3 alleles. What is
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Other pharmacologic therapy: ursodiol
Several years ago, Essell and colleagues 72 published their results of a randomized trial of ursodiol for prevention of VOD. Patients were prepared with busulfan and cyclophosphamide and received methotrexate plus cyclosporine as GVHD prophylaxis. VOD occurred in 40% of placebo recipients and 15% of ursodiol recipients. While development of VOD was the strongest predictor of survival to day 100 post transplant, day 100 survival was not statistically different between the two groups. More recently, a second randomized trial of ursodiol was conducted in Japan. VOD occurred significantly less often in the ursodiol-treated patients (3%) compared with the control group (18%). Again, no statistically significant difference was observed in survival between the two groups. 73 There are data which show that bile steroids may prevent endothelial cell 74 and hepatocyte injury, 75 possibly by downregulating the expression of inflammatory mediators. How it may actually work to prevent VOD is unclear.
Non-pharmacologic therapy: transjugular intrahepatic portosystemic shunting (TIPS)
Several groups have reported using TIPS for the treatment of VOD. In this procedure, a channel is created between the hepatic and portal vein using a percutaneously inserted catheter and kept patent with a metal stent. A total of 19 patients have been reported in the literature. [76] [77] [78] [79] Significant reduction in hepatic venous pressure gradient was reported after the procedure. Eight patients had no improvement in VOD and died within 2 weeks. Of the remaining 11 patients, improvement in ascites, urinary output, and coagulation parameters was noted. Unfortunately, all but three died of other complications. There is some suggestion from the report of Azoulay and colleagues, 79 that responding patients have less severe disease, as demonstrated by lower bilirubin and ALT prior to the TIPS and a greater reduction in the hepatic venous pressure gradient after the procedure. In addition, their patients who died shortly after TIPS had a shorter interval from transplant to TIPS than patients who survived more than 10 days, suggesting that the pace of their disease was faster. These data indicate that TIPS may benefit more than half of patients with VOD. However, they also indicate that these patients have other life-threatening problems, as well.
Conclusion
We have known for a long time that patients with active liver injury, as indicated by elevated transaminases prior to the start of preparative therapy, were more likely to develop severe VOD. Recent data indicate that the endothelial damage and repair processes are ongoing at the start of conditioning in many patients, as evidenced by elevated baseline levels of PIIINP, 21 vWF and thrombomodulin 60 in patients who develop VOD. Prophylaxis might be more effective if it were directed towards endothelial protection and reduction of fibrosis. Further study of agents like NAC or l-glutamine, which would target endothelial protection by supplementing sources of glutathione, are warranted. How to stop ongoing fibrosis is unclear. If such prophylactic strategies are ineffective, it is doubtful that treatment of VOD will ever be better than the 30-35% reported for defibrotide. Most patients, even if successfully treated, die of other complications. This inability may be less problematic than it appears, however. New nonmyeloablative immunosuppressive strategies are being actively studied and preliminary reports using these regimens suggest that VOD occurs less frequently. Conceivably, we may be closer to transplantation with little regimen-related toxicity. Whether we get there by figuring out how to interfere with VOD pathogenesis or by circumventing the problem really does not matter.
